Tennis elbow treatments for ulcers are still under consideration in the United States, with some physicians and patients still unsure of whether the treatments work, according to the American College of Sports Medicine.
The American College’s committee on treatment for COVID/emergent diseases (TCEDs) issued a statement Friday, saying that it’s “still in the early stages” of its review of a drug called Olysium.
The committee, which was convened in March to assess whether Olysum could be used to treat ulcers, said it is still gathering information on the drug.
“There is not enough information on this drug to provide a clear recommendation,” the statement said.
In recent weeks, the medical community has been discussing whether a drug to treat COVID has been approved by the Food and Drug Administration (FDA).
Olysia, the first drug approved by FDA for COVI, has been used in people with recurrent COVID infections, but there are concerns about its efficacy, and a separate study in adults with COVID found that it did not help.
Olysiastroline is marketed under the trade name Olysiolex.
If approved, the drug would be the first COVID treatment approved by FASD.
It would be administered through a small tube, and would need to be taken by mouth.
The committee also issued a call to Congress for a study to evaluate the safety and effectiveness of Olysiosolex and other treatments for patients with chronic ulcers.
“If the results of the ongoing safety studies are published, it is our expectation that FDA will approve Olysiolic for COV-19 treatment,” the committee said.